Fulvestrant and the sequential endocrine cascade for advanced breast cancer

British Journal of Cancer

Volumn 90, Issue , 2004, Pages S15-S18

  Johnston, S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Endocrine therapy; Faslodex; Fulvestrant; Sequencing

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CAPECITABINE; CISPLATIN; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GOSERELIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS;

EID: 1842784776     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601632     Document Type: Article

References (25)

1. ATAC Trialists Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139.
2. Borras M, Laios I, el Khissiin A, Seo HS, Lempereur F, Legros N, Leclercq G (1996) Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 57: 203-213.
3. Buzdar AU, Hortobagyi G (1998) Update on endocrine therapy for breast cancer. Clin Cancer Res 4: 527-534.
4. Carlson RW (2002) Sequencing of endocrine therapies in breast cancer - integration of recent data. Breast Cancer Res Treat 75(Suppl 1): S27-S32.
5. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M (2002) Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 81: 333-341.
6. Dauvois S, White R, Parker MG (1993) The antiestrogen ICI 182780. disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106(Part 4): 1377-1388.
7. Franco S, Perez A, Tan-Chiu E, Frankel C, Vogel C (2003) Fulvestrant (Faslodexs) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer: a single-center experience. Breast Cancer Res Treat 82(Suppl 1): S105 (abstract 429)
8. Hortobagyi GN (1998) Progress in endocrine therapy for breast carcinoma. Cancer 83: 1-6.
9. Howell A (2002) Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res Treat 76(Suppl 1): S72. (abstract 251)
10. Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403.
11. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S, Santen RJ (1998) Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139: 4164-4174.
12. Johnston SR (2001) Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res 7: 4376s-4387s
13. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278: 30458-30468.
14. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101-2109.
15. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18: 3758-3767.
16. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395.
17. Perey L, Thürlimann B, Hawle H, Bonnefoi H, Ahern J, Pagani O, Goldhirsch A, Dietrich D (2002) Fulvestrant (‘faslodex’) as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors Breast Cancer Res Treat 76(Suppl 1): S72 (abstract 249)
18. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M (2001) Comparison of the short-term biological effects of 7-alpha-[9-(4, 4, 5, 5, 5- pentafluoropentylsulfinyl)-nonyl]estra-1, 3, 5, (10)-triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61: 6739-6746.
19. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials. Cancer 98: 229-238.
20. Robertson JFR, Howell A, Abram P, Lichinitser M, Elledge R (2002) Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women. Ann Oncol 13(Suppl 5): 46 (abstract 1640)
21. Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R, Santen RJ (2000) Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141: 396-405.
22. Steger G, Bartsch R, Wenzel C, Pluschnig U, Locker G, Mader RM, Zielinski CC (2003a) Fulvestrant (‘Faslodex’) demonstrates clinical benefit in heavily pre-treated patients with metastatic breast cancer. Eur J Cancer 1(Suppl 5): S135.
23. Steger G, Bartsch R, Wenzel C, Pluschnig U, Locker G, Mader RM, Zielinski CC (2003b) Fulvestrant beyond the second hormonal treatment line in metastatic breast cancer. Proc Am Soc Clin Oncol 22: 20.
24. Vergote I, Robertson JFR, Kleeberg U, Burton G, Osborne CK, Mauriac L (2003) Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 79: 207-211.
25. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873